Speaker Lecture Titles
PARTIAL LIST OF CONFIRMED SPEAKERS
Surname |
First name |
Country |
Title |
|---|---|---|---|
| Aarsland | Dag | UK | DIAGNOSTIC AND PROGNOSTIC BIOMARKERS OF DEMENTIA WITH LEWYBODIES: NEW FINDINGS FROM THE EUROPEAN DLB CONSORTIUM |
| Au | Rhoda | USA | ACCELERATING DISCOVERY OF DIGITAL BIOMARKERS FOR ALZHEIMER’S DISEASE |
| Babic | Tomislav | Austria | CHALLENGES OF DRUG DEVELOPMENT IN L-DOPA NAÏVE SUBJECTS WITH DIAGNOSIS OF EARLY PARKINSON’S DISEASE |
| Blennow | Kaj | Sweden | MONITORING BRAIN AMYLOIDOSIS, TAU PATHOLOGY AND NEURODEGENERATION BY PLASMA MEASUREMENTS, PROGRESS TOWARDS RELIABLE AND SENSITIVE TESTS. |
| Bu | Goujun | USA | TREM2 AND ITS AD RISK VARIANTS IN MICROGLIAL FUNCTIONS AND ALZHEIMER’S DISEASE |
| Buee | Luc | France | FROM GENE TRANSFER TO ANTIBODY: WHICH DEVELOPMENT FOR TAU IMMUNOTHERAPY |
| Cattaneo | Annamaria | Italy | ROLE OF THE GUT MICROBIOTA, INFLAMMATION AND THEIR INTERPLAY IN THE PATHOGENESIS AND PROGRESSION OF ALZHEIMER DISEASE |
| Checler | Frédéric | France | BETA-CTF: A KEY PLAYER LINKED TO AUTOPHAGIC/LYSOSOMAL DYSFUNCTION |
| Chiba-Falek | Ornit | USA | NEXT-GENERATION GENE THERAPY FOR PRECISION MEDICINE IN AGE-RELATED NEURODEGENERATIVE DISEASES: TARGETED EPIGENOME EDITING TO REVERSE SNCA DYSREGULATION IN PD |
| Cleveland | Don | USA | GENERATING NEW NEURONS IN THE ADULT MAMMALIAN NERVOUS SYSTEM: CONVERTING ASTROCYTES INTO NEURONS PRODUCES THERAPEUTIC REVERSAL OF CHEMICALLY INDUCED PARKINSON DISEASE |
| Cudkowics | Merit | USA | ALS PLATFORM TRIAL INITIATIVE: ACCELERATING THERAPY DEVELOPMENT |
| Cuello | Claudio | Canada | IS THE NGF METABOLIC PATHWAY A PROMISING CANDIDATE FOR AD BIOMARKERS AND THERAPY? |
| Eberling | Jamie | USA | ACCELERATING THERAPEUTIC DEVELOPMENT FOR PARKINSON’S DISEASE |
| Engelborghs | Sebastiaan | Belgium | RATIONAL USE OF FLUID BIOMARKERS IN ALZHEIMER’S DISEASE CLINICAL TRIALS |
| Ferretti | Maria Teresa | Switzerland | SEX AND GENDER DIFFERENCES IN ALZHEIMER’S DISEASE – GATEWAY TO PRECISION MEDICINE |
| Fillit | Howard | USA | TRANSLATING THE BIOLOGY OF AGING INTO NEW DRUGS FOR ALZHEIMER’S DISEASE: A VENTURE PHILANTHROPY APPROACH |
| Fox | Nick | United Kingdom | INSIGHTS FROM IMAGING OF INDIVIDUALS AT RISK OF FAMILIAL AD |
| Frisoni | Giovanni | Switzerland | FECAL TRANSPLANTATION TO PREVENT ALZHEIMER’S DISEASE: PRECLINICAL STUDIES |
| Froelich | Luz | Germany | CONCLUSIONS FROM THE NEGATIVE PHASE III TRIALS – HOW TO ADAPT DRUG DEVELOPMENT IN AD |
| Galvin | James | USA | CAN DEMENTIA BE PREVENTED: NEW LESSONS LEARNED AND APPLIED IN RESEARCH AND CLINICAL PRACTICE |
| Gerwert | Klaus | Germany | MISFOLDING OF Aβ AS PRECISE PLASMA BIOMARKER FOR PRECLINICAL ALZHEIMER`S |
| Geula | Changiz | USA | ANATOMIC, CELLULAR AND MOLECULAR SIGNATURES OF SUPERIOR COGNITIVE PERFORMANCE IN OLD AGE. |
| Giacobini | Ezio | Switzerland | USING CHOLINESTERASE INHIBITORS TO TREAT ALZHEIMER PATIENTS AT DIFFERENT STAGES OF THE DISEASE. WHAT WE HAVE LEARNED IN 25Y EXPERIENCE! |
| Gold | Gabriel | Switzerland | MICROSCOPIC VASCULAR LESIONS: CAN WE SEE THEM? DOES IT MATTER? |
| Grinberg | Lea | USA | IMPROVING TREATMENT FOR SLEEP DYSFUNCTION IN NEURODEGENERATIVE DISEASES: LESSONS FROM HUMAN NEUROPATHOLOGICAL STUDIES |
| Growdon | John | USA | ANTI-ABETA AND ANTI-TAU TREATMENTS WILL BENEFIT PARKINSON DISEASE |
| Hannson | Oskar | Sweden | FLUID AND PET IMAGING MARKERS OF TAU PATHOLOGY IN THE DIAGNOSTIC WORK-UP OF DEMENTIA DISORDERS |
| Hansen | David | USA | MICROGLIAL ITAM AND ITIM IMMUNORECEPTORS AS THERAPEUTIC TARGETS FOR ALZHEIMER’S DISEASE |
| Hartmann | Tobias | Germany | LONG-TERM EFFECTS OF MULTI NUTRIENT INTERVENTION IN THE PRODROMAL AD LIPIDIDIET CLINICAL TRIAL |
| Heneka | Michael | Germany | MICROGLIAL PATHOLOGY DRIVES NEURONAL DYSFUNCTION AND DEGENERATION IN ALZHEIMER’S DISEASE |
| Hornberger | Michael | UK | SEA HERO QUEST – A CITIZEN SCIENCE APPROACH TOWARDS BIG DATA IN ALZHEIMER’S DISEASE |
| Hort | Jakub | Czech Republic | CHALLENGES OF DRUG DEVELOPMENT: SUBJECTS IN CLINICAL TRIALS AND REAL PATIENTS AT MEMORY CLINIC |
| Hyman | Bradley | USA | THE ROLE OF TAU IN ALZHEIMER’S PROGRESSION |
| Iwatsubo | Takeshi | Japan | TOWARD VERY EARLY TREATMENT OF ALZHEIMER’S DISEASE |
| Jagust | William | USA | TAU IMAGING, MEMORY, AND THE BEGINNING OF ALZHEIMER’S DISEASE |
| Jeon | Beomsoek | Korea | PERIPHERAL TISSUE BIOMARKERS IN PD AND THEIR IMPLICATION |
| Kloppel | Stefan | Switzerland | MACHINE LEARNING & IMAGING FOR NEURODEGENERATIVE DISORDERS |
| Korczyn | Amos | Israel | MILD COGNITIVE IMPAIRMENT IN PD |
| Korolev | Igor | Switzerland | DATA SCIENCE & DIGITAL HEALTH: CHALLENGES & OPPORTUNITIES (PANEL) |
| Korolev | Igor | Switzerland | DATA SCIENCE & DIGITAL HEALTH: CHALLENGES & OPPORTUNITIES (PANEL) |
| Koroshetz | Walter | USA | NIH RESEARCH: NEW FOCUS ON DEMENTIA WITH LEWY BODIES |
| Kulisevsky | Jamie | Spain | HALLUCINATIONS IN PD: CLINICAL AND NEUROIMAGING CORRELATES |
| Marek | Ken | USA | DEVELOPING A PD PRODROMAL BIOMARKER SIGNATURE |
| Masliah | Eliezer | USA | NIA/NIH PERSPECTIVE ON AD CLINICAL TRIALS |
| Michaelson | Daniel | Israel | APOE4 TARGETED THERAPY OF ALZHEIMER’S DISEASE BASED ON ACTIVATION OF THE LIPIDATING TRANSPORTER ABCA1 |
| Molinuevo | José Luis | Spain | EARLY CHANGES IN AD BIOMARKERS SHOWN AN INTERPLAY BETWEEN TAU METABOLISM, INFLAMMATION, SYNAPTIC DAMAGE AND NEURODEGENERATION |
| Mollenhauer | Brit | Germany | HOW TO DIAGNOSE LEWY BODY DISEASE ACCURATELY AND MORE EARLY? |
| Morris | John | USA | “WHAT WE CAN LEARN FROM FAMILIAL AD?”. |
| Nordberg | Agneta | Sweden | TAU PET TRACERS, HOW SPECIFIC FOR AD AND NON –AD TAUOPATHIES – STILL A DILEMMA? |
| Outeiro | Tiago | Germany | THE MOLECULAR BASIS FOR THE SPREADING OF ALPHA-SYNUCLEIN: THERAPEUTIC TARGETS FOR INTERVENTION |
| Poewe | Werner | Austria | NOVEL APPROACHES TO DISEASE-MODIFICATION IN PD |
| Rabinovici | Gil | USA | PET IMAGING IN NON-AD TAUOPATHIES: PROGRESS AND CHALLENGES |
| Rascol | Oliver | France | CURRENT AND FUTURE APPROACHES OF THE PHARMACOLOGICAL MANAGEMENT OF OFF EPISODES IN PARKINSON DISEASE |
| Rektorova | Irena | Czech Republic | COMBINATORIAL BIOMARKER ANALYSIS IN LEWY BODY DISEASES |
| Scheltens | Philip | The Netherlands | NEW BLOOD MARKERS FOR ALZHEIMER’S: WHERE DO WE STAND? |
| Schlossmacher | Michael | Canada | LRRK2 AND A-SYNUCLEIN FUNCTIONS IN INNATE IMMUNITY: LESSONS FOR TARGETED THERAPY IN PARKINSON’S |
| Schmidt | Reinhold | Austria | MRI-DETECTED IRON DEPOSITION IN NORMAL AGING AND DEMENTIA |
| Schmitz | Taylor | United Kingdom | BASAL FOREBRAIN DEGENERATION PREDICTS MICROGLIAL DYSFUNCTION AND INFLAMMATION IN COGNITIVELY NORMAL ADULTS WITH ABNORMAL AMYLOID AND TAU |
| Sisodia | Sangram | USA | REGULATION OF AD-TYPE NEUROPATHOLOGICAL HALLMARKS BY THE GUT MICROBIOME |
| Smith | Meg | USA | TBA |
| Snyder | Heather | USA | ALZHEIMER’S ASSOCIATION FUNDING OPPORTUNITIES: ACCELERATING RESEARCH IN ALL DEMENTIA |
| Solomon | Beka | Israel | MOBILIZATION OF ENDOGENOUS HEMATOPOIETIC SYSTEM FOR TREATMENT OF ALZHEIMER’S DISEASE |
| Soreq | Hermona | Israel | NEAT1 ELEVATION UNDER OXIDATIVE STRESS CONFERS LRRK2-MEDIATED PROTECTION OF PARKINSON’S SUBSTANTIA NIGRA NEURONS |
| Stocchi | Fabrizio | Italy | A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PARKINSON’S DISEASE: IS IT A PROMISING STRATEGY? |
| Stephenson | Diane | USA | CRITICAL PATH FOR PARKINSON’S CONSORTIUM |
| Tanzi | Rudy | USA | THE ROLE OF MICROBES AND INNATE IMMUNE GENES IN ALZHEIMER’S DISEASE |
| Taylor | Kirsten | Switzerland | DIGITAL BIOMARKERS FOR PARKINSON’S DISEASE |
| Vassar | Robert | USA | BACE1 IN ALZHEIMER’S DISEASE |
| Vemuri | Prashanthi | USA | IMAGING MARKERS OF RESILIENCE AND RESERVE IN ALZHEIMER’S DISEASE |
| Villemagne | Victor | Australia | TAU IMAGING IN AD AND NON-AD TAUOPATHIES |
| Weiner | Michael | USA | IMAGING AND BIOFLUID BIOMARKERS TO OPTIMIZE AD CLINICAL TRIALS: ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI) AND BRAIN HEALTH REGISTRY |
| Weiner | Howard | USA | INNATE IMMUNE MECHANISMS IN ALZHEIMER’S DISEASE AND THE ROLE OF THE MICROBIOME |
| Wong | Philip | USA | FUNCTIONAL VALIDATION OF TDP-43 SPLICING REPRESSION AS A THERAPEUTIC TARGET FOR ALS-FTD |
| Xu | Huaxi | USA | A HUMAN ESC-DERIVED MICROGLIA MULTIOMIC AND FUNCTIONAL PLATFORM REVEALS CONVERGENT PATHOGENIC POTENTIAL FOR ALZHEIMER’S VARIANTS |
| Yamada | Masahito | Japan | TRANSMISSION OF ABETA PATHOLOGY LEADING TO EARLY-ONSET CEREBRAL AMYLOID ANGIOPATHY IN HUMANS |
| Zhou | Jiawei | China | ROLE OF NG2 GLIA IN THE REGULATION OF NEUROINFLAMMATION: IMPLICATION IN PARKINSON’S DISEASE. |